艾米珠单抗在获得性血友病A中持续生存获益并推迟免疫抑制治疗
GTH-AHA-EMI研究纳入47例获得性血友病A患者,在初始12周使用艾米珠单抗预防出血并推迟免疫抑制治疗,2年总生存率为82%,而倾向评分匹配的GTH-AH 01/2010历史对照(n=101,立即免疫抑制治疗)为63%(HR 0.39,95%CI 0.19-0.80)。感染相关死亡率艾米珠单抗组为4%对16%,出血相关死亡率相似(4%对3%)。推迟免疫抑制治疗安全有效,完全缓解时间较长(44 vs 16周),但完全缓解比例相似(76% vs 66%)。
要点
- 艾米珠单抗预防出血并推迟免疫抑制治疗,2年总生存率82% vs 匹配历史对照63%(HR 0.39,95%CI 0.19-0.80)。
- 感染相关死亡率艾米珠单抗组4% vs 对照组16%,出血相关死亡率相似(4% vs 3%)。
- 推迟免疫抑制治疗完全缓解时间较长(44 vs 16周),但完全缓解比例相似(76% vs 66%)。
核心结论
- 在GTH-AHA-EMI研究中,艾米珠单抗允许在获得性血友病A早期管理中推迟免疫抑制治疗启动,推迟免疫抑制治疗安全有效。
- 与接受立即免疫抑制治疗但未用艾米珠单抗的倾向评分匹配历史对照相比,GTH-AHA-EMI患者致命感染更少且总生存改善。
研究设计与样本
- GTH-AHA-EMI研究收集47例患者的2年随访数据,与GTH-AH 01/2010研究倾向评分匹配队列(n=101,立即免疫抑制治疗)比较。
- GTH-AHA-EMI研究在初始12周使用艾米珠单抗预防出血并推迟免疫抑制治疗。
- 研究队列在年龄、性别、基础疾病、基线FVIII活性、抑制物滴度和体能状态方面匹配良好。
- 该试验在ClinicalTrials.gov注册,注册号NCT04188639。
主要发现
- 倾向评分匹配的2年总生存率在GTH-AHA-EMI队列为82%,GTH-AH 01/2010为63%(HR 0.39,95%CI 0.19-0.80)。
- 感染相关死亡率艾米珠单抗组为4% vs 对照组16%,出血相关死亡率相似(4% vs 3%)。
- GTH-AHA-EMI患者中15%发生获得性血友病A自发缓解。
- Kaplan-Meier法估计的完全缓解时间在推迟免疫抑制治疗的GTH-AHA-EMI组较长(44 vs 16周),但估计达到完全缓解的患者比例相似(76% vs 66%)。
临床怎么用
- 作者认为,在获得性血友病A早期管理中,艾米珠单抗允许推迟免疫抑制治疗启动,推迟免疫抑制治疗安全有效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acquired hemophilia A (AHA) is a severe bleeding disorder caused by neutralizing autoantibodies against coagulation factor VIII (FVIII). Standard treatment involves immunosuppressive therapy (IST), which carries a significant risk of serious infections, the leading cause of death in patients with AHA. The GTH-AHA-EMI study investigated the use of emicizumab to prevent bleeding during the first 12 weeks of management while postponing IST. We collected 2-year follow-up data from GTH-AHA-EMI patients (n = 47) and compared outcomes to a propensity score (PS)-matched cohort from the GTH-AH 01/2010 study (n = 101), in which patients received immediate IST. Outcome measures included overall survival (OS), infection- and bleed-related mortality, and time to complete remission (CR). The study cohorts were well-matched in age, sex, underlying conditions, baseline FVIII activity, inhibitor titer, and performance status. The PS-matched 2-year OS was 82% in the GTH-AHA-EMI cohort vs 63% in GTH-AH 01/2010 (hazard ratio, 0.39; 95% confidence interval, 0.19-0.80). Infection-related mortality was lower with emicizumab (4% vs 16%), whereas bleed-related mortality was similar (4% vs 3%). Spontaneous remission of AHA occurred in 15% of GTH-AHA-EMI patients. Time to CR estimated by the Kaplan-Meier method was longer with postponed IST in GTH-AHA-EMI (44 vs 16 weeks), but the estimated proportion of patients achieving CR was similar (76% vs 66%). In conclusion, emicizumab allowed for postponed IST initiation during early AHA management in the GTH-AHA-EMI study. Delayed IST was safe and effective. Compared to PS-matched historic controls receiving immediate IST but no emicizumab, GTH-AHA-EMI patients had fewer fatal infections and improved OS. This trial was registered at www.ClinicalTrials.gov as #NCT04188639.
引用
- Schimansky IM, Dobbelstein C, Klamroth R, et al. Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A. Blood Adv. 2025. PMID: 40795229. doi:10.1182/bloodadvances.2025017144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。